Overview of QUILT 3032 Study of N-803 Plus BCG in NMIBC

Sam S. Chang, MD, MBA, discusses the research of N-803 in combination with BCG in patients with BCG-unresponsive non-muscle invasive bladder cancer.

Sam S. Chang, MD, MBA, professor Department of Urology, Patricia and Rodes Hart Professor of Urologic Surgery, and chief surgical officer and chief of the Division of Urologic Oncology at Vanderbilt Ingram Cancer Center, discusses the research of N-803 in combination with BCG in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

A presentation given at the 2022 American Urologic Association Annual Meeting further explained the results of the QUILT 3032 study (NCT03022825) of N-803 plus BCG in this patient population.

Findings revealed that 71% of patients who had failed on previous therapies demonstrated over a 50% increase in response and median duration compared to other FDA-approved alternatives, such as valrubicin and pembrolizumab (Keytruda), a systemic checkpoint inhibitor therapy for this indication.

Transcription:

0:08 | This trial looked at a combination of BCG, which is a commonly used medication to treat patients with non-muscle invasive bladder cancer and combine it with a novel agent or compound called N-803, which is a formulated agonist or super agonist of IL-15. This combination was used in patients who previously were treated with BCG, but did not have a response or had a tumor that came back resistant to BCG.


0:43 | What we found was in patients with both carcinoma in side 2, as well as papillary disease, that's non-invasive bladder cancer, these patients that were heavily pretreated with this combination therapy had excellent results with very few side effects. That's the bottom line.